Home LiteratureArticle Details
PMID: 24251364 Published · ppublish English Editorial Comment

Do pharmacogenetics have a role in the dosing of vitamin K antagonists?

The New England journal of medicine ·Vol. 369 ·No. 24 ·2013-12-12 ·Pages 2345-6

Furie B

Abstract

暂无摘要

MeSH Terms
Acenocoumarol/administration & dosage Algorithms Anticoagulants/administration & dosage Aryl Hydrocarbon Hydroxylases/genetics Cytochrome P-450 CYP2C9 Female Genotype Humans Male Phenprocoumon/administration & dosage Vitamin K Epoxide Reductases/genetics Warfarin/administration & dosage
Chemicals
Anticoagulants Warfarin CYP2C9 protein, human Cytochrome P-450 CYP2C9 Aryl Hydrocarbon Hydroxylases VKORC1 protein, human Vitamin K Epoxide Reductases Acenocoumarol Phenprocoumon
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Furie Bruce
From Harvard Medical School and the Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center - both in Boston.
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJMe1313682
Published
2013-12-12
Epub
2013-00-19
Pages
2345-6
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentOn
PMID: 24251360
CommentOn
PMID: 24251361
CommentOn
PMID: 24251363
External Links
PubMed source DOI: 10.1056/NEJMe1313682 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2